|Day's Range||6.50 - 6.50|
Cytokinetics (CYTK) delivered earnings and revenue surprises of -5.66% and 4.88%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Completed Enrollment in GALACTIC-HF with More than 8,200 Heart Failure Patients Results from Phase 1 Study of CK-274 to be Presented at HFSA in September 2019; Phase 2 Clinical.
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics, Incorporated (CYTK) today announced that preclinical data for CK-3773274 (CK-274) were presented at the American Heart Association’s Basic Cardiovascular Sciences (BCVS) Scientific Sessions in Boston, showing that CK-274 decreased cardiac contractility in vitro, in vivo in healthy animals, and in vivo in a mouse model of hypertrophic cardiomyopathy (HCM). CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of HCM which may result from increased cardiac contractility.
Biotech real estate developer Kilroy is happy with leasing at its 2.5 million-square-foot Oyster Point project, a fast-growing San Francisco tech company is moving researchers off paper — and more in our Health Care Digest.
If you own shares in Cytokinetics, Incorporated (NASDAQ:CYTK) then it's worth thinking about how it contributes to the...
Years in the making — and still two years from opening — Kilroy Oyster Point lines up its first lease with a longtime South San Francisco biotech company.
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report second quarter results on August 8, 2019 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
Cytokinetics, Incorporated (CYTK) today announced the publication of data in The Journal of Physiology demonstrating that a fast skeletal muscle troponin activator (FSTA) can decrease skeletal muscle fatigue by increasing the metabolic efficiency of muscle contraction. The manuscript, titled “Fast Skeletal Muscle Troponin Activator CK-2066260 Increases Fatigue Resistance by Reducing the Energetic Cost of Muscle Contraction,” was published this month. Cytokinetics conducted the research in collaboration with the laboratory of Professor Håkan Westerblad at the Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Cytokinetics, Incorporated (CYTK) today announced that the European Medicines Agency (EMA) has granted orphan medicinal product designation to reldesemtiv for the potential treatment of spinal muscular atrophy (SMA). In collaboration with Astellas, Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
SOUTH SAN FRANCISCO, Calif., July 22, 2019 -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that two preclinical poster presentations relating to CK-3773274.
Cytokinetics, Incorporated (CYTK) today announced the completion of patient enrollment in GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil which is being conducted by Amgen, in collaboration with Cytokinetics. Omecamtiv mecarbil, a novel investigational cardiac muscle activator, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.
Cytokinetics, Incorporated (CYTK) today announced that data from two preclinical studies of reldesemtiv were presented at the 2019 Annual Cure SMA Conference in Anaheim, CA, showing that the addition of reldesemtiv to treatment with SMN upregulators (nusinersen and SMN-C1, an analogue to risdiplam) significantly increased muscle force in a mouse model of spinal muscular atrophy (SMA). In collaboration with Astellas, Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA), as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn't that high to begin with. This is usually a negative indicator. At the end of this article we will also compare CYTK to other stocks including The York Water Company (NASDAQ:YORW), Green Brick Partners Inc (NASDAQ:GRBK), […]
SOUTH SAN FRANCISCO, Calif., June 24, 2019 -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv.
A look at the shareholders of Cytokinetics, Incorporated (NASDAQ:CYTK) can tell us which group is most powerful...
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19, 2019 at 9:00 AM EST at the St. Regis Hotel in New York. Interested parties may access the live webcast of this presentation by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.
Cytokinetics, Incorporated (CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. “The ALS Association and The ALS Association Golden West Chapter have been exceptional partners over the many years we’ve worked together in supporting patients, caregivers, and advocates of our ALS community,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 54 cents per share. The biopharmaceutical company posted revenue of $8.5 million in the period. Cytokinetics shares have increased ...